Annual report pursuant to Section 13 and 15(d)

Aytu Divestiture - Summary of Cash Flows (Details)

v3.20.4
Aytu Divestiture - Summary of Cash Flows (Details) - USD ($)
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Operating activities    
Change in fair value of Guarantee $ (1,755,000) $ 0
Gain on Aytu Divestiture 0 (7,964,924)
Pediatric Portfolio    
Operating activities    
Gain on Aytu Divestiture   (8,000,000.0)
Pediatric Portfolio | Discontinued Operations, Disposed of by Sale    
Operating activities    
Amortization 0 2,425,083
Impairment of intangible assets 0 1,449,121
Stock-based compensation, excluding amount included within gain on sale of Pediatric Portfolio 0 327,180
Amortization of inventory fair value adjustment associated with acquisition of TRx and Avadel pediatric product 0 107,271
Change in fair value of contingent consideration 0 247,042
Change in fair value of Guarantee (1,755,000) 0
Gain on Aytu Divestiture $ 0 $ (7,964,924)